Adding laser-induced chorioretinal anastomosis to anti-VEGF treatment for central retinal vein occlusion can reduce the number of injections needed, according to a study.
A randomized clinical trial included 58 patients with macular edema caused by CRVO who received monthly 0.5 mg Lucentis (ranibizumab, Genentech) intravitreal injections and were randomly assigned 1:1 to undergo either a laser-induced chorioretinal anastomosis procedure in addition to anti-VEGF or a sham procedure.
From month 7 to 13, the mean number of ranibizumab injections in the combination group was 1.5 compared with 2.4
Uncategorized